Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy | Zendy

Jihye Kim | Zendy; Vihas T. Vasu | Zendy; Rangnath Mishra | Zendy; Katherine R. Singleton | Zendy; Minjae Yoo | Zendy; Sonia M. Leach | Zendy; Eveline FariasHesson | Zendy; Robert J. Mason | Zendy; Jaewoo Kang | Zendy; Preveen Ramamoorthy | Zendy; Jeffrey A. Kern | Zendy; Lynn E. Heasley | Zendy; James H. Finigan | Zendy; Aik Choon Tan | Zendy

Open Access

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy

Author(s) -

Jihye Kim,

Vihas T. Vasu,

Rangnath Mishra,

Katherine R. Singleton,

Minjae Yoo,

Sonia M. Leach,

Eveline FariasHesson,

Robert J. Mason,

Jaewoo Kang,

Preveen Ramamoorthy,

Jeffrey A. Kern,

Lynn E. Heasley,

James H. Finigan,

Aik Choon Tan

Publication year - 2014

Publication title -

bioinformatics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.599

H-Index - 390

eISSN - 1367-4811

pISSN - 1367-4803

DOI - 10.1093/bioinformatics/btu323

Subject(s) - gefitinib , epidermal growth factor receptor , erlotinib , egfr inhibitors , lung cancer , cancer , kinase , drug repositioning , bosutinib , cancer research , repurposing , biology , tyrosine kinase , medicine , pharmacology , oncology , signal transduction , genetics , drug , dasatinib , ecology

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in the United States. Targeted tyrosine kinase inhibitors (TKIs) directed against the epidermal growth factor receptor (EGFR) have been widely and successfully used in treating NSCLC patients with activating EGFR mutations. Unfortunately, the duration of response is short-lived, and all patients eventually relapse by acquiring resistance mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research